📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 19:59
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
6 announcements match the current filters (relevance ≥ 5).
Nova Agritech Q1 Standalone PAT Up 188% YoY to Rs 1.36 Cr; Revenue Rises 80% to Rs 21.00 Cr
Nova Agritech reported standalone revenue from operations of Rs 20.9975 Cr for the quarter ended June 30, 2026, an 80.2% YoY increase compared to Rs 11.6517 Cr in Q1 FY26. Standalone net profit for the period grew 188.6% YoY to Rs 1.36 Cr (Rs 136.49 lakhs) compared to Rs 0.47 Cr (Rs 47.30 lakhs) in the prior-year period. Standalone quarterly EPS expanded to Rs 0.15 compared to Rs 0.05 in Q1 FY26. Additionally, the company scheduled its 19th AGM for September 26, 2026, and re-appointed key whole-time directors.
Confidence: HIGH
What changedNova Agritech released its Q1 FY27 standalone financial results showing strong YoY earnings recovery and approved key leadership re-appointments.
Why it mattersThe earnings rebound indicates better capacity utilization and demand recovery after a sluggish prior-year base, supporting operational stability.
Standalone Revenue (Q1): Rs 2,099.75 lakhsStandalone PAT (Q1): Rs 136.49 lakhsStandalone EPS (Q1): Rs 0.15AGM Date: 26th September, 2026
📅 Short termStrong YoY recovery in revenue and profitability may offer short-term positive sentiment for the stock after extended price declines.
📈 Long termSustained valuation re-rating will require the company to scale towards its targeted Rs 300+ Cr revenue threshold while improving high debtor days and cash conversion.
⚠ Risk flags
- High working capital intensity and extended debtor cycle
- High sensitivity to monsoon conditions and seasonal agrochemical demand
Key Highlights
Standalone revenue from operations reached Rs 2,099.75 lakhs (Rs 21.00 Cr), up 80.2% YoY from Rs 1,165.17 lakhs in Q1 FY26.
Standalone profit after tax surged 188.6% YoY to Rs 136.49 lakhs (Rs 1.36 Cr) against Rs 47.30 lakhs in Q1 FY26.
Basic and diluted standalone EPS increased to Rs 0.15 for the quarter compared to Rs 0.05 in the corresponding prior-year quarter.
Board approved the re-appointment of Whole-Time Directors Mrs. Malathi Siripurapu and Mr. Rajesh Cherukuri for 3-year terms, and set AGM for September 26, 2026.
👀 What to Watch
Track whether production from the expanded manufacturing facilities continues to translate into steady revenue growth and monitor working capital cycle improvement in upcoming quarterly disclosures.
Nova Agritech FY26 Consolidated Net Profit Drops 53% to ₹12.84 Cr Amid License Renewal Delays
Nova Agritech Limited reported a challenging fiscal year 2025-26, with consolidated net profit declining 53.2% to ₹1,283.84 lakhs compared to ₹2,742.20 lakhs in the previous year. Consolidated revenue from operations fell 11% to ₹26,159.42 lakhs. The standalone business was significantly impacted, with revenue halving to ₹7,801.50 lakhs due to a temporary suspension of biostimulant product sales following a delay in the Fertiliser Marketing Authorization License renewal. Management confirmed the license was renewed in January 2026 and operations have since fully resumed.
Key Highlights
Consolidated Net Profit for FY26 decreased by 53.2% YoY to ₹1,283.84 lakhs from ₹2,742.20 lakhs.
Standalone revenue declined by 53% to ₹7,801.50 lakhs due to a 7-month lapse in the Fertiliser Marketing Authorization License.
Consolidated revenue from operations for the full year stood at ₹26,159.42 lakhs, down from ₹29,413.16 lakhs in FY25.
The company successfully renewed its biostimulant license on January 20, 2026, after it had lapsed in June 2025.
Board approved the re-appointment of V P S & Associates as Internal Auditors and M P R & ASSOCIATES as Cost Auditors for FY 2026-27.
👀 What to Watch
Investors should closely monitor the Q1 FY27 results to verify the management's claim of a full recovery following the license renewal. While the FY26 numbers are weak, the resolution of the regulatory hurdle suggests the downturn may be cyclical rather than structural.
Nova Agritech FY26 Consolidated Net Profit Drops 53% to ₹12.84 Cr Amid License Delays
Nova Agritech Limited reported a sharp decline in its financial performance for the fiscal year ended March 31, 2026. Consolidated revenue fell 11% YoY to ₹261.59 crore, while consolidated net profit plummeted 53.2% to ₹12.84 crore compared to ₹27.42 crore in the previous year. The standalone business was severely impacted, with revenue halving to ₹78.02 crore due to a temporary suspension of biostimulant product operations following a delay in the renewal of the Fertiliser Marketing Authorization License.
Key Highlights
Consolidated Net Profit for FY26 decreased by 53.2% YoY to ₹1,283.84 lakhs from ₹2,742.20 lakhs.
Standalone revenue for the year plummeted 53% to ₹7,801.50 lakhs from ₹16,585.58 lakhs in FY25.
The company's Fertiliser Marketing Authorization License lapsed on June 16, 2025, and was only renewed on January 20, 2026, causing a 7-month operational disruption.
Consolidated Earnings Per Share (EPS) dropped significantly to ₹1.43 from ₹3.05 in the previous fiscal year.
Management stated that operations have fully resumed following the license renewal and the decline is temporary rather than structural.
👀 What to Watch
Investors should exercise caution and closely monitor the Q1 FY27 results to verify if the resumption of operations leads to a swift recovery in margins. The significant impact of a single license renewal highlights a regulatory risk that investors must factor into their long-term valuation.
Nova Agritech Credit Outlook Revised to Negative by CARE Ratings Amid Liquidity Stress
CARE Ratings has reaffirmed Nova Agritech's long-term rating at 'CARE BBB' but revised the outlook from 'Stable' to 'Negative'. The revision is driven by a decline in Q3FY26 performance following a government stay on bio-stimulants, which previously contributed 30% of revenue. The company is currently facing stretched liquidity, with receivables reaching ₹214 crore and working capital utilization at a high 96%. Although the company received 43 new product approvals in January 2026, the elongated operating cycle of 217 days remains a significant risk factor.
Key Highlights
Outlook revised to Negative from Stable; Long-term rating reaffirmed at CARE BBB.
9MFY26 revenue fell to ₹206 crore vs ₹214 crore YoY, with PBILDT dropping to ₹23.92 crore.
Bio-stimulant segment (30% of revenue) was severely impacted by regulatory changes in July 2025.
Receivables stood at ₹214 crore as of Dec 31, 2025, with 55% outstanding for more than six months.
Operating cycle elongated to 217 days in FY25, leading to 96% utilization of bank limits.
👀 What to Watch
Investors should exercise caution due to the stretched liquidity and high receivables; focus on the company's ability to recover sales through the 43 newly approved products. Monitor the next two quarters for improvements in the working capital cycle and reduction in bank limit utilization.
Nova Agritech Q3 FY26 Net Profit Drops 75% YoY to ₹2.61 Crore; Revenue Down 24.5%
Nova Agritech reported a significant decline in its consolidated financial performance for the quarter ended December 31, 2025. Consolidated revenue from operations fell by 24.5% YoY to ₹66.55 crore compared to ₹88.19 crore in the same quarter last year. Net profit (PAT) saw a sharp contraction of 75.2%, dropping to ₹2.61 crore from ₹10.56 crore YoY. For the nine-month period, PAT also declined by 41.6% to ₹12.62 crore, reflecting significant margin pressure.
Key Highlights
Consolidated revenue decreased by 24.5% YoY to ₹6,654.57 lakhs in Q3 FY26.
Consolidated Profit After Tax (PAT) plummeted 75.2% YoY to ₹261.23 lakhs from ₹1,055.80 lakhs.
9M FY26 consolidated PAT stood at ₹1,261.80 lakhs, down from ₹2,160.98 lakhs in the previous year.
Standalone revenue for the quarter saw a sharp decline to ₹2,446.79 lakhs from ₹4,322.53 lakhs YoY.
Company confirmed full utilization of IPO proceeds as of September 30, 2025, with no deviations reported.
👀 What to Watch
The results indicate a severe deterioration in operational performance and profitability, suggesting significant headwinds in the agri-input segment. Investors should remain cautious and monitor management's commentary regarding the sharp decline in margins and revenue.
Nova Agritech Secures Approval for 43 Additional Biostimulant Products in Telangana
Nova Agritech Limited has received an amendment to its Biostimulants License from the Department of Agriculture, Government of Telangana, authorizing the addition of 43 new products. These products span various categories including botanical extracts, humic acids, and seaweed extracts tailored for major crops like paddy, tomato, and chilli. The manufacturing will be conducted at the company's existing formulation plant in Singannaguda, Telangana. This regulatory approval is valid until September 29, 2029, providing a clear runway for the company to expand its market presence and revenue potential in the biostimulant segment.
Key Highlights
Approval granted for 43 additional biostimulant products by the Government of Telangana.
Product range includes high-concentration formulations like Humic Acid 76% and various seaweed extracts.
The amended license remains valid for a long-term period ending September 29, 2029.
Manufacturing to be centralized at the Singannaguda formulation plant to leverage existing operational capabilities.
👀 What to Watch
Investors should consider this a positive development for the company's product diversification and long-term growth. Monitor the upcoming quarterly earnings to see how quickly these new products are commercialized and their impact on margins.
